AB Science S.A
Save
51.47M
Market cap
–
Current P/E
–
Forward P/E
About
Health care
Sector
Drug Manufacturers - Specialty & Generic
Industry
AB Science S. A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19.
Similar securities
Based on sector and market capitalization
Report issue